Relation of short-latency afferent inhibition to the cholinergic system

MCG0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Willingness to cooperate and sign written informed consent
•-Clinical diagnosis of idiopathic Parkinson’s disease by a neurologist with disease duration between 5 and 15 years.

•-Incapable to provide informed consent (e.g. in case of severe dementia)
•-Treatment with drugs with anticholinergic activity, as listed in Chew et al. 2008 and Ehrt et al. 2010
•-Current or recent treatment with ChEIs
•-Presence of deep brain stimulation implants
•-(Suspected) pregnancy
•-Participation in a scientific research study during the past year involving radiation
•-MRI contra-indications, e.g.
•oFerrous objects in or around the body (e.g. braces, pacemaker, metal fragments)
•oClaustrophobia
•-Insufficient knowledge of the Dutch language
•Control subjects:
•-History of neurological or neurodegenerative disorder
•-Moderate to severe cognitive impairment, but no dementia, according to diagnostic criteria
•-Unsafe or irresponsible to postpone treatment with ChEIs, according to treatment provider

发起方

MCG